HGH Fragment 176-191 corresponds to the C-terminal region of human growth hormone and is studied mainly in preclinical and early experimental settings. This page describes hypothesized and investigational effects, not established treatments.
Overview
HGH Fragment 176-191 is the segment of growth hormone (amino acids 176-191) that researchers associated with the hormone's effects on fat. Interest in the fragment comes almost entirely from this metabolic angle:
- Potential effects on the breakdown of stored fat (lipolysis).
- The hypothesis that a small piece of growth hormone could carry its fat-related activity.
- The possibility of avoiding growth hormone's broader effects on IGF-1 and blood sugar.
These are the reasons the fragment is studied; they are not a promise of any specific cosmetic or clinical result.
Fat metabolism and body composition
In preclinical models, the C-terminal fragment has been examined for its ability to influence fat metabolism, and this is the source of most body-composition interest. Users often discuss it alongside training and diet in the hope of supporting fat loss.
- The proposed effect is on how fat is mobilized and used for energy.
- Findings come largely from laboratory and animal work rather than large human trials.
- Any translation to visible body-composition change in healthy adults is unproven.
The idea of a separated fat-loss signal
The central appeal of HGH Fragment 176-191 is conceptual: full-length growth hormone affects growth, IGF-1, and glucose handling as well as fat, and those broader effects are undesirable in a fat-loss context. Researchers hypothesized that the C-terminal fragment might isolate the fat-related signal from the rest. Whether this separation holds up as a meaningful clinical advantage in humans remains an open question rather than a demonstrated benefit.
How it compares to AOD-9604
HGH Fragment 176-191 is closely related to AOD-9604, which was developed as a modified, stabilized analog of the same fragment:
- HGH Fragment 176-191 — the native C-terminal sequence of growth hormone.
- AOD-9604 — an engineered version intended to be more stable, and the form that reached formal clinical testing.
Notably, the more thoroughly studied analog produced underwhelming fat-loss results in later trials, which tempers expectations for the parent fragment.
Evidence and caveats
The fragment has an appealing mechanistic story, but a compelling story is not the same as proven benefit. Key caveats:
- It is not an FDA-approved therapy in the United States.
- Human fat-loss evidence, including for its analog AOD-9604, has been weak.
- Product purity and labeling vary in the research-chemical market.
- Long-term safety in healthy people has not been established.